• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Neogen Announces Third-Quarter Earnings Release Date

    3/20/25 4:15:00 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $NEOG alert in real time by email

    LANSING, Mich., March 20, 2025 /PRNewswire/ -- Neogen® Corporation (NASDAQ:NEOG) will issue its third-quarter earnings release before the opening of the market on Wednesday, April 9, 2025. Executives from the company will host a webcast and conference call later that morning, beginning at 8:00 a.m. Eastern time, to discuss the financial results.

    Neogen Corporation (PRNewsfoto/Neogen Corporation)

    The conference call can be accessed by dialing:

    Toll-Free - North America: 1-800-549-8228

    International: (+1) 646-564-2877

    Conference ID: 63045

    The live webcast can be accessed through Neogen's Investor Relations webpage, neogen.com/investor-relations, under the "Events & Presentations" subheading.

    A replay of the conference call and webcast will be available shortly following the conclusion of the call and can be accessed by dialing:

    Toll-Free - North America: 1-877-674-7070

    International: (+1) 416-764-8692

    Passcode: 63045 #

    It will also be available on Neogen's Investor Relations website at neogen.com/investor-relations.

    About Neogen

    Neogen Corporation is committed to fueling a brighter future for global food security through the advancement of human and animal well-being. Harnessing the power of science and technology, Neogen has developed comprehensive solutions spanning the Food Safety, Livestock, and Pet Health & Wellness markets. A world leader in these fields, Neogen has a presence in over 140 countries with a dedicated network of scientists and technical experts focused on delivering optimized products and technology for its customers.  

    Contact

    [email protected]

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/neogen-announces-third-quarter-earnings-release-date-302407462.html

    SOURCE Neogen Corporation

    Get the next $NEOG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NEOG

    DatePrice TargetRatingAnalyst
    7/29/2025Outperform → Mkt Perform
    William Blair
    12/19/2024$15.00Buy
    Guggenheim
    6/16/2023$22.00Overweight
    Wells Fargo
    11/22/2022Mkt Perform → Outperform
    William Blair
    7/12/2022$25.00Neutral
    Piper Sandler
    More analyst ratings

    $NEOG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Neogen Announces Second-Quarter 2026 Results

    Revenue of $224.7 million, a decrease of 2.8% YoY; Core growth1 increased 2.9% YoY Net loss of $15.9 million; Adjusted Net Income1 of $22.6 million Adjusted EBITDA1 of $48.7 million; Adjusted EBITDA margin1 increased 470 bps sequentially Company hires key senior commercial leaders Petrifilm manufacturing transition remains on track Raising FY 2026 revenue and Adjusted EBITDA guidance 1 Non-GAAP financial measures; see explanations and reconciliations that follow Neogen Corporation (NASDAQ:NEOG) announced today the results of the second quarter ended November 30, 2025. "I am exceptionally proud of the Neogen team as we have initiated the first phase of our strategic tr

    1/8/26 7:00:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen® Announces Two Senior Leadership Appointments

    Neogen Corporation (NASDAQ:NEOG) today announced the appointments of Joe Freels as Senior Vice President and Chief Commercial Officer, effective January 5, 2026, and Dr. Tammi Ranalli as Senior Vice President and General Manager, Global Food Safety, effective January 7, 2026. As Senior Vice President and General Manager for Neogen's Food Safety business unit, Dr. Ranalli will have full P&L responsibility for Neogen's global Food Safety portfolio and will develop and execute the global strategy for continued innovation and growth, including marketing, research and development, and government and regulatory affairs. She joins Neogen from QuidelOrtho, where she served as Senior Vice Presiden

    1/5/26 8:45:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen Announces Second-Quarter Earnings Release Date

    Neogen® Corporation (NASDAQ:NEOG) will issue its second-quarter earnings release before the opening of the market on January 8, 2026. Executives from the company will host a webcast and conference call later that morning, beginning at 8:00 a.m. Eastern time, to discuss the financial results. The conference call can be accessed by dialing: Toll-Free - North America: 1-800-549-8228 International: (+1) 646-564-2877 Conference ID: 82072 The live webcast can be accessed through Neogen's Investor Relations webpage, investors.neogen.com, under the "Events & Presentations" subheading. A replay of the conference call and webcast will be available shortly following the conclusion of the call and c

    12/18/25 9:00:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NEOG
    SEC Filings

    View All

    SEC Form 10-Q filed by Neogen Corporation

    10-Q - NEOGEN CORP (0000711377) (Filer)

    1/8/26 4:07:39 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - NEOGEN CORP (0000711377) (Filer)

    1/8/26 7:03:05 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen Corporation filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - NEOGEN CORP (0000711377) (Filer)

    10/30/25 8:47:15 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NEOG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO Nassif Mikheal bought $1,106 worth of shares (177 units at $6.25) (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    11/7/25 12:20:20 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Gupta Aashima bought $99,987 worth of shares (16,000 units at $6.25), increasing direct ownership by 270% to 21,917 units (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    5/12/25 2:30:47 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Woteki Catherine E bought $29,831 worth of shares (5,770 units at $5.17), increasing direct ownership by 77% to 13,244 units (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    4/25/25 4:32:35 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NEOG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Neogen downgraded by William Blair

    William Blair downgraded Neogen from Outperform to Mkt Perform

    7/29/25 3:32:27 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Guggenheim initiated coverage on Neogen with a new price target

    Guggenheim initiated coverage of Neogen with a rating of Buy and set a new price target of $15.00

    12/19/24 8:18:19 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Wells Fargo initiated coverage on Neogen with a new price target

    Wells Fargo initiated coverage of Neogen with a rating of Overweight and set a new price target of $22.00

    6/16/23 7:34:39 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NEOG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Former CFO Naemura David H. exercised 12,912 shares at a strike of $5.98 and covered exercise/tax liability with 3,548 shares, increasing direct ownership by 12% to 90,388 units (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    12/2/25 11:45:31 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    CEO Nassif Mikheal bought $1,106 worth of shares (177 units at $6.25) (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    11/7/25 12:20:20 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: New insider Nassif Mikheal claimed ownership of 620 shares (SEC Form 3)

    3/A - NEOGEN CORP (0000711377) (Issuer)

    11/7/25 12:12:52 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NEOG
    Leadership Updates

    Live Leadership Updates

    View All

    Neogen® Corporation Announces Appointment of Bryan Riggsbee as Chief Financial Officer

    Neogen® Corporation (NASDAQ:NEOG), a global leader of food safety solutions, is pleased to announce the appointment of Bryan Riggsbee as its new Chief Financial Officer effective November 3, 2025. Riggsbee will oversee Neogen's global finance organization and join the company's Executive Leadership Team, reporting directly to Chief Executive Officer Mike Nassif. To ensure a smooth transition, David Naemura is expected to remain with the Company until the end of the calendar year. Riggsbee brings over 25 years of financial leadership experience across the diagnostics and healthcare industries. He joins Neogen from bioMérieux where he served as Chief Financial Officer of its $2 billion Nort

    10/30/25 8:45:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen Announces Board Transition with Appointment of Avi Pelossof and the Retirement of William Boehm

    Neogen® Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, announced today that William Boehm has chosen to retire from the Company's Board of Directors, effective October 23, 2025. Mr. Boehm has served on Neogen's Board since 2011 and currently serves on the Compensation & Talent Management Committee and chairs the Audit Committee. "On behalf of the entire Board and leadership team, I want to express our deep gratitude to Bill for his many years of dedicated service to Neogen," said James C. Borel, Chair of the Neogen Board of Directors. "Bill's insight, guidance, and commitment to our mission have been invaluable in shaping Neogen's path forward. His contributions

    8/14/25 4:15:00 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen® Corporation Announces Appointment of Mike Nassif as CEO and President

    Neogen® Corporation (NASDAQ:NEOG), a global leader of food safety solutions, is pleased to announce the appointment of Mike Nassif as its new Chief Executive Officer and President, effective August 11, 2025. He also will join Neogen's Board of Directors at that time. Mr. Nassif succeeds John Adent who will, as previously announced, step down after an eight-year career at the company. Mr. Nassif brings a wealth of experience and a proven track record of success in the healthcare and diagnostics industry. Mr. Nassif joins Neogen from Siemens Healthineers, where he was Global President of the Point-of-Care Diagnostics business and instrumental in driving significant growth. "I am very exci

    7/24/25 9:00:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NEOG
    Financials

    Live finance-specific insights

    View All

    Neogen Announces Second-Quarter 2026 Results

    Revenue of $224.7 million, a decrease of 2.8% YoY; Core growth1 increased 2.9% YoY Net loss of $15.9 million; Adjusted Net Income1 of $22.6 million Adjusted EBITDA1 of $48.7 million; Adjusted EBITDA margin1 increased 470 bps sequentially Company hires key senior commercial leaders Petrifilm manufacturing transition remains on track Raising FY 2026 revenue and Adjusted EBITDA guidance 1 Non-GAAP financial measures; see explanations and reconciliations that follow Neogen Corporation (NASDAQ:NEOG) announced today the results of the second quarter ended November 30, 2025. "I am exceptionally proud of the Neogen team as we have initiated the first phase of our strategic tr

    1/8/26 7:00:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen Announces Second-Quarter Earnings Release Date

    Neogen® Corporation (NASDAQ:NEOG) will issue its second-quarter earnings release before the opening of the market on January 8, 2026. Executives from the company will host a webcast and conference call later that morning, beginning at 8:00 a.m. Eastern time, to discuss the financial results. The conference call can be accessed by dialing: Toll-Free - North America: 1-800-549-8228 International: (+1) 646-564-2877 Conference ID: 82072 The live webcast can be accessed through Neogen's Investor Relations webpage, investors.neogen.com, under the "Events & Presentations" subheading. A replay of the conference call and webcast will be available shortly following the conclusion of the call and c

    12/18/25 9:00:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen Announces First-Quarter 2026 Results

    Revenue of $209.2 million Net Income of $36.3 million; Adjusted Net Income1 of $9.4 million Adjusted EBITDA1 of $35.5 million Completed divestiture of Cleaners & Disinfectants business, repaid $100.0 million of debt Welcomed Mike Nassif as Chief Executive Officer and President, effective August 11 Restructuring actions taken at the end of September to right-size the cost base Reaffirming full-year outlook 1 Non-GAAP financial measures; see explanations and reconciliations that follow Neogen Corporation (NASDAQ:NEOG) announced today the results of the first quarter ended August 31, 2025. "I see tremendous opportunity ahead to leverage Neogen's strong, longstanding l

    10/9/25 7:00:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NEOG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Neogen Corporation

    SC 13G - NEOGEN CORP (0000711377) (Subject)

    11/14/24 4:28:12 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G filed by Neogen Corporation

    SC 13G - NEOGEN CORP (0000711377) (Subject)

    11/14/24 11:16:20 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G/A filed by Neogen Corporation (Amendment)

    SC 13G/A - NEOGEN CORP (0000711377) (Subject)

    2/13/24 5:09:41 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care